AzTrials
AzTrials

COVID-19MDNCT04424940

COVID-19 Lessons Learned: the Outcome of TOMEKA® Project is to Teach

An observational study of COVID-19, run by University of Kinshasa at 1 site in Democratic Republic of the Congo.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Living in Canada and being health-worker in the first line face to COVID-19, investigator outcome is to teach an experience or explain the disease using a review and get people prepared to COVID-19 treatment focused on adherence to the HIV approved 2006-2007 protocol at Ghent University but the review shows an older… Read more about this study

Who is it for?
Ages 15 to 75 yearsHealthy volunteers can take part
Conditions the study is for
COVID-19
How many people
800 participants
Where
1 siteDemocratic Republic of the Congo
Study dates
1 Sep 2020to 1 Sep 2021
How long will I take part?
9 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: * Age: 15-75 * Sex: M, F

Who may be able to join

  • Fulfill Inclusion criteria and accept
  • COVID-19 patients confirmed
  • be regular on appointments

Who cannot join

  • COVID-19 suspected clinically
  • Children
  • refuse to participate

Trial locations and contacts

1 site in 1 country.

GUYGUY KABUNDI TSHIMA, MD contact

5143819264

guyguytshima@yahoo.fr

Democratic Republic of the Congo1 site
  • Cliniques Universitaires de Kinshasa

    Kinshasa, BP KIN XI

    GUYGUY K. TSHIMA, Dr., 0015143819264, guyguytshimakabundi@gmail.com

Other trials in Democratic Republic of the Congo

About this study

Official title: TOMEKA® Project Was Sponsored by the University of Kinshasa: it's an Observational Study by Its Reviewed Documentation

Living in Canada and being health-worker in the first line face to COVID-19, investigator outcome is to teach an experience or explain the disease using a review and get people prepared to COVID-19 treatment focused on adherence to the HIV approved 2006-2007 protocol at Ghent University but the review shows an older different study approved at the University of Kinshasa and its ethics approval that again is an old document. So no ethics document supporting the study exists as it is now and no registration. It is an observational study and therefore would not usually require registration in order for the results to be published. It is not a type of secondary literature. The formula TOMEKA® (Mix porridge of maize, sorghum, and soya) follows FOOD + HEALTH CLAIM. It is scientifically justified, relevantly used, and correctly communicated. Methodology: sufficient data? scientific consensus? correct methodology? correct population? context: significant results? context of use, realistic ingestion? correct target group? communication: consumer perception? exaggerated/insinuative, clear, precise, complete, correct information? not misleading? correctly presented? The product TOMEKA® tried to fulfill to above questions in a fitting way with COVID-19 which is an emerging, rapidly evolving situation without a vaccine.

Read the detailed description

On 12/06/2020 worldwide, COVID-19 affected 7 273 958 confirmed cases with 413 372 deaths, 97 894 confirmed in Canada with 8 048 deaths, 53 666 confirmed cases in Quebec with 5 148 deaths, 4 637 confirmed cases with 101 deaths in the Democratic Republic of the Congo where the situation is disastrous: an immense country and the ways of communication are difficult and damaged. It becomes gymnastics to get a drug package.

The principal investigator provide the details of this study to be available to the public in getting knowledge of Covid-19 and micronutrients using the product TOMEKA®.

The individual contribution of ingredients in the nutritional composition of TOMEKA® (mixed flour). Composition of TOMEKA® (Clinical Research Protocol): 100 g of TOMEKA contain 20.1 g of protein; 57.8 g of carbohydrates, 10.1 g of lipids; 8.5 mg iron; 117.6 mg Calcium; 16.6 mg Sodium; 55 μg of Selenium and 378.6 kcal of energy.TOMEKA will be made with soy, maize, sorghum. The above calculations were made with the food composition table (no laboratory analyzes).

Quantity to be served per meal (in g): 30 g for 6-8 months (113,4 Kcal of Energy per served meal). 40 g for 9-11 months (151 Kcal): 50 g for 12-23 months and more expecting to provide 189 Kcal of energy per served per meal. Each group needs 4-5 meals a day to get the equivalent of their daily nutritional needs.

The study will focus on Selenium, a powerful non-enzymatic antioxidant, more powerful than Vit C and Vit E combined. The formula TOMEKA® follows FOOD + HEALTH CLAIM.

A clear device to follow micronutrients and Covid-19 symptoms:

Example 1: Vitamin D and Covid-19 (Press release from the National Academy of Medicine in France May 22, 2020) Vitamin D is a prohormone synthesized in the dermis under the effect of ultraviolet rays, that is to say of the rays of the sun, then transported in the liver and the kidney where it is transformed into an active hormone. It is responsible for the intestinal absorption of calcium and bone health, but vitamin D also has unconventional effects. In particular, it modulates the functioning of the immune system by stimulating macrophages and dendritic cells [1,2,3]. It plays a role in regulating and suppressing the cytokine inflammatory response which causes acute respiratory distress syndrome which characterizes the severe and often lethal forms of Covid-19. A significant correlation between low serum vitamin D levels and mortality by Covid-19 has been shown [4]. This phenomenon generally follows a North-South gradient, although there are exceptions such as the Nordic countries where the supplementation of the nutrients in vitamin D, in particular milk products, is systematic. On the other hand, the countries of southern Europe surprisingly display a high prevalence of vitamin D deficiency despite higher sunshine [5]. This would explain why children who receive vitamin D regularly have asymptomatic forms of Covid-19 and fewer complications. Vitamin D cannot be considered as a preventive or curative treatment for SARS-CoV-2 infection; but by mitigating the inflammatory storm and its consequences, it could be considered as an adjunct to any form of therapy.

The National Academy of Medicine in France recalls that the administration of vitamin D orally is a simple, inexpensive measure and reimbursed by Health Insurance; - confirms its recommendation to ensure vitamin D supplementation in the French population in a report in 2012 [2]; - recommend that the serum vitamin D level (i.e. 25OHD) be measured quickly in people over 60 years of age with Covid-19 and that it be administered in the event of a deficiency, a loading dose of 50,000 to 100,000 IU which could help limit respiratory complications; - recommends providing vitamin D supplementation of 800 to 1,000 IU / day in people under the age of 60 as soon as the diagnosis of Covid-19 is confirmed.

Example 2: Selenium and Covid-19

Now is the time to give extra attention to a balanced diet and assure an optimum dietary micronutrient and vitamin intake! Particularly the micronutrient selenium plays an essential role in antioxidant functioning and helps to alleviate the negative health impacts of viral infections, including inflammation of the lungs (see e.g. https://lnkd.in/eqAGhDH).

Particularly elderly people are often selenium-deficient, which was proven to be the case in e.g. Italy (see https://lnkd.in/epFKVEY). However, when taking micronutrient and vitamin supplements, also follow the instructions to avoid over-supplementation! A healthy and balanced diet is the safest way towards an appropriate dietary micronutrient and vitamin intake.

Description of what investigators will measure:

  1. The Production of Medical Knowledge:
  2. Learning medicine:

How it will be measured:

  1. The Production of Medical Knowledge: Anthropology/Medicine. It is substantial and it showed by the title.
  2. Learning medicine: The clinical trial shows that medical anthropology connects anthropology and social theory generally with some of the more significant questions of our epoch with the COVID-19 pandemic.

And at what time points it will be measured:

  1. The Production of Medical Knowledge: the principal investigator has received notifications from Researchgate about 700 researchers who read his research theme, so it deserves to be widely read and taught.
  2. Learning medicine: This is an original trial, which combines theoretical argument with empirical observation

Objectives:

  1. Investigators would like the participant to accept the notion that all knowledge is socially and culturally constructed.
  2. Investigators would examine the contexts in which that knowledge is produced talking on the theme of nutrition in research and aiming to act in medicine, psychiatry, epidemiology, and anthropology.
  3. Investigators would like the participant acts in behavioral medicine, public health, epidemiology, anthropology as well as .nutrition.

The hypothesis of investigators work:

  1. Patients with COVID-19 have an increased demand for Selenium
  2. Selenium supplementation reduces the viral rate
  3. Selenium supplementation improves the BMI of COVID-19 patients
  4. Selenium supplementation reduces COVID-19 related morbidity
  5. Selenium supplementation postponed COVID-19 related mortality
  6. Selenium supplementation is adjuncted to any form of COVID-19 therapy with nutrition education
  7. Nutrition education improves health status
  8. Selenium supplementation and nutrition education should be incorporated into the global Nutritional care and support of COVID-19 patients Methodology: observational study using a questionnaire. Study Population: Age: 15-75 Sex: M, F Inclusion Criteria: Fulfill Inclusion criteria and accept: The participant is asked on the symptoms of the COVID-19 with a questionnaire. If he/she can write yes to any of these questions in order to be tested: In the past 4 hours, have you taken any medicines for fever or headaches, such as acetaminophen (Paracetamol, Tylenol, Tempra), ibuprofen (Advil, Motrin) or Aspirin? Yes No Do you have a thermometer to take your body temperature? Yes No If you don't have a thermometer, do you have any of the following symptoms: warm forehead, muscle or joint pain, chills, general weakness? Yes No In the past 24 hours, have you had trouble breathing or been short of breath? Yes No In the past 24 hours, have you had chest pain? Yes No Do you have a cough? Or if you have a health condition that is causing you to cough, is your cough worse than usual? Yes No In the past 24 hours, have you had a sore throat? Yes No In the past 24 hours, have you had a runny nose? Yes No In the past 24 hours, have you felt a loss of smell (in the absence of nasal congestion)? Yes No In the past 24 hours, have you had diarrhea (three or more bowel movements)? Yes No In the past 24 hours, have you had a headache? Yes No In the past 24 hours, have you felt more tired than usual and unable to carry out your daily activities? Yes No COVID-19 patients confirmed be regular on appointments Exclusion Criteria: COVID-19 suspected clinically Children refuse to participate Initial assessment for the exclusion of suspected Covid-19 cases:
  • New or exacerbated cough: Yes/No
  • Sore throat: Yes/No
  • Fever: Yes/No
  • Intestinal gastritis symptoms (Diarrhea, nausea or vomiting): Yes/No
  • Anosmia (loss of smell) / Ageusia (loss of taste): Yes/No
  • Shortness of breath: Yes/No
  • Sputum production: Yes/No
  • Weakness: Yes/No
  • Headache: Yes/No
  • Myalgia / athralgia: Yes/No
  • Nasal congestion: Yes/No
  • Hemoptysis: Yes/No
  • Conjunctivitis: Yes/No Comments: If yes to any of these questions: rule out an acute health condition. If no acute cause identified, consider the person as a probable case and transfer to the warm unit.
  1. Atypical geriatric signs
  • Sudden loss of autonomy (less than 1 week)
  • Sudden change in mental state (over 1 week)
  • Sudden change in behavior (new behavior or cessation of behavior (less than 1 week)
  • Geriatric fever (Oral or rectal temperature greater than or equal to 37.8 C or if increase of 1.1 C compared to the usual normal T)

Other comments:

………………………………………………………………………………………………………….. ........................................................................................................................................................................................................................................................................................................................................................................................................................................................

  1. Physical examination inspection:
  • Assessment of mental state
  • Attention span: attentive, not attentive
  • State of consciousness: hyper-alert (or agitation), Lethargic (verbal), alert stupor (physical, comatose
  1. Basic settings:

Vital signs:

Pulse: ……… / min TA: .......... / ……………. T: ................ C (fever if bu oral or rectal sup or equal 37.8 C or if 1.1 C increase compared to the usual normal T)

Breathing:

Frequency: ......... / min

Type: Abdominal chest

Amplitude: normal deep surface

Rhythm: regular irregular

Draw: yes no

Saturation (normal to 94% and +, unless otherwise indicated):

Saturation: ............% ambient AIr With O2 …… ..L / min

  1. Auscultation:

Anterior side

Abnormal noise: Yes No

Name if possible:

Sibilant

Ronchis

Right bronchus (A)

Left bronchus (B)

Posterior side

Presence of abnormal noise:

Yes

No

Name if possible:

Sibilant

Crackling

Lower right row

Left lower lobe

  1. Medical decision making

Prescribed screening test (oro-nasopharyngeal sample): yes no

If the sample confirms the presence of COVID-19, isolate the patient in the warm unit.

  1. Clinical monitoring of COVID-19 confirmed or suspected

Stable patient

Respiratory rate : q 2h and as needed

SpO2 and Temperature: per day and as needed

Blood pressure and Cardiac frequency: per day

Unstable patient (having had an episode of respiratory distress)

Respiratory rate: every hour and as needed

SpO2 and Temperature: per day and as needed

Surname and first name of doctor

Permits

Signature

DD / MM / YYYY

HH: MM

References:

  1. - Liu PT, Stenger S, et al. Toll like receptor triggering of a vitamin D mediated humanantimicrobial response. Science, 2006, 311 : 1770.
  2. - Rapport de l'Académie nationale de médecine. Statut vitaminique, rôle extra osseux etbesoins quotidiens en vitamine D. Bull Acad Natle Med. 2012, 196, 1011.
  3. - Laird E, Rhodes JM and Kenny RA. Vitamin D and inflammation : potential implications for severity of Covid-19. Irish med J, 2020, 113 : 81.
  4. - McCartney DM, Byrne DG. Optimisation of vitamin D status impact mortality fromSARS -CoV-2 infection Irish Med J .2020 113 : 58.5- Lips P, Cashman KD, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency : a position statement of the European Calcified Tissue Society. Eur J Endocrinol, 2019, 180 : P23-P54.

Links:

https://lnkd.in/eqAGhDH https://lnkd.in/epFKVEY

Conditions
COVID-19
Keywords
TOMEKA®, Treatment, COVID-19, Education
Medical subject headings
COVID-19

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants with treatment-TOMEKA® usage as assessed by Education

    Change people's behaviour

    Measured: 9 months

Secondary outcomes (1)
  1. Change From Baseline in nutraceuticals usage on the care of the Covid-19 at 9 months

    Change people's behaviour

    Measured: 9 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jun 2020
  2. Study start1 Sep 2020 (estimated)
  3. Primary completion1 Jun 2021 (estimated)
  4. Study completion1 Sep 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
800 participants (estimated)
Target duration
9 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT04424940
Sponsor's protocol ID
UKinshasa
Other IDs
Tshima Guyguy Kabundi
Acronym
MD
Status last verified
Jun 2020
First submitted
20 May 2020
Last updated
16 Jun 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Through researchgate website

Publications

  • This phenomenon generally follows a North-South gradient, although there are exceptions such as the Nordic countries where the supplementation of the nutrients in vitamin D, in particular milk products, is systematic. On the other hand, the countries of southern Europe surprisingly display a high prevalence of vitamin D deficiency despite higher sunshine

  • This would explain why children who receive vitamin D regularly have asymptomatic forms of Covid-19 and fewer complications. Vitamin D cannot be considered as a preventive or curative treatment for SARS-CoV-2 infection; but by mitigating the inflammatory storm and its consequences, it could be considered as an adjunct to any form of therapy.

  • The National Academy of Medicine in France recalls that the administration of vitamin D orally is a simple, inexpensive measure and reimbursed by Health Insurance; - confirms its recommendation to ensure vitamin D supplementation in the French population in a report in 2012 [2]; - recommend that the serum vitamin D level (i.e. 25OHD) be measured quickly in people over 60 years of age with Covid-19, and that it be administered in the event of a deficiency , a loading dose of 50,000 to 100,000 IU which could help limit respiratory complications; - recommends providing vitamin D supplementation of 800 to 1,000 IU / day in people under the age of 60 as soon as the diagnosis of Covid-19 is confirmed.

  • Now is the time to give extra attention to a balanced diet and assure an optimum dietary micronutrient and vitamin intake! Particularly the micronutrient selenium plays an essential role in antioxidant functioning and helps to alleviate negative health impacts of viral infections, including inflammation of the lungs

  • Particularly elderly people are often selenium-deficient, which was proven to be the case in e.g. Italy

  • However, when taking micronutrient and vitamin supplements, also follow the instructions to avoid over-supplementation! A healthy and balanced diet is the safest way towards an appropriate dietary micronutrient and vitamin intake.

  • Vitamin D is a prohormone synthesized in the dermis under the effect of ultraviolet rays, that is to say of the rays of the sun, then transported in the liver and the kidney where it is transformed into an active hormone. It is responsible for the intestinal absorption of calcium and bone health, but vitamin D also has unconventional effects. In particular, it modulates the functioning of the immune system by stimulating macrophages and dendritic cells.

  • It plays a role in regulating and suppressing the cytokine inflammatory response which causes acute respiratory distress syndrome which characterizes the severe and often lethal forms of Covid-19. A significant correlation between low serum vitamin D levels and mortality by Covid-19 has been shown.

Questions about this trial

What is this clinical trial studying?

An observational study of COVID-19, run by University of Kinshasa at 1 site in Democratic Republic of the Congo.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 16 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Democratic Republic of the Congo. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact TSHIMA, MD (15143819264, guyguytshimakabundi@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants with treatment-TOMEKA® usage as assessed by Education (time frame: 9 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04424940, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in